Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival.
Juliane ManitzSandra P D' AngeloAndrea B ApoloS Peter EggletonMarcis BajarsOliver BohnsackJames L GulleyPublished in: Journal for immunotherapy of cancer (2022)
The use of irRECIST identified a subset of patients with a BOR of PD by RECIST 1.1 but an irBOR of immune-related disease control by irRECIST with a distinctive survival curve, thereby providing more clinically relevant information than RECIST 1.1 alone. However, as a surrogate endpoint for OS in the whole population, immune-related PFS by irRECIST did not show improved predictive value compared with PFS by RECIST 1.1.
Keyphrases